Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BZAD-01 is an antagonist of NR2B subunit-containing NMDA receptors (Ki = 72 nM).1 It is selective for NR2B subunit-containing NMDA receptors over those containing NR2A subunits in a calcium mobilization assay (IC50s = 47 and >10,000 nM, respectively). Oral administration of BZAD-01 reduces hyperalgesia induced by carrageenan in rats (ED50 = 5.5 mg/kg). BZAD-01 (10 mg/kg) reduces dopaminergic neuron loss in the rat substantia nigra pars compacta and improves measures of ipsilateral curling, ipsilateral head positioning, and beam walking in a rat model of Parkinson’s disease induced by the catecholaminergic neurotoxin 6-OHDA (Item No. 25330).2
WARNING This product is not for human or veterinary use.
1. Orally efficacious NR2B-
2. Neuroprotective effects of a selective N-